We have previously reported that ovarian cancer patients with platinum-refractory disease, who were treated with IP IL-2 and responded favorably, had markedly increased eosinophils and serum CXCL11/eotaxin at the completion of treatment. The gene discussed is CXCL11; the disease is ovarian carcinoma.